A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

NCT01676558 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory Diffuse Large B Cell Lymphoma

Interventions

DRUG: 131I-rituximab

Sponsor

Korea Cancer Center Hospital